Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors

Area of Science:

• Medicinal Chemistry
• Oncology Drug Discovery

Background:

• c-Met signaling pathway dysregulation is implicated in various cancers, particularly gastric cancer.
• Development of targeted therapies inhibiting c-Met is a key strategy in cancer treatment.

Purpose of the Study:

• To discover and optimize novel, potent, and selective small molecule inhibitors of c-Met.
• To identify drug candidates with favorable pharmacokinetic properties and in vivo antitumor activity.

Main Methods:

• Structure-based drug design principles were employed.
• Iterative chemical synthesis and optimization of the triazolothiadiazole scaffold.
• In vitro kinase selectivity assays and ADME profiling.
• In vivo evaluation of antitumor efficacy in a gastric cancer xenograft model.

Main Results:

• A novel series of triazolothiadiazole c-Met inhibitors was identified.
• Metabolically stable quinoline moiety replaced the phenolic group, leading to compound 21.
• Compound 23 exhibited exquisite kinase selectivity, high potency, and a favorable ADME profile.
• Compound 23 demonstrated dose-dependent antitumor efficacy in a SNU-5 gastric cancer xenograft model.

Conclusions:

• Compound 23 represents a promising drug candidate for gastric cancer treatment.
• The triazolothiadiazole scaffold is a viable platform for developing potent and selective c-Met inhibitors.
• Structure-based design and iterative optimization are effective strategies for advancing oncology drug discovery.